{"id":1658,"date":"2024-07-16T21:29:38","date_gmt":"2024-07-16T13:29:38","guid":{"rendered":"https:\/\/flcube.com\/?p=1658"},"modified":"2024-10-15T14:21:25","modified_gmt":"2024-10-15T06:21:25","slug":"novo-nordisk-faces-us-senators-scrutiny-over-levemir-withdrawal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1658","title":{"rendered":"Novo Nordisk Faces US Senators&#8217; Scrutiny Over Levemir Withdrawal"},"content":{"rendered":"\n<p>US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo Nordisk&#8217;s (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/NOVO-B:CPH\">CPH: NOVO-B<\/a>) decision to discontinue the sales of its long-acting insulin brand Levemir (insulin detemir) in the US market. The company announced in November 2023 its intention to cease distribution by the end of 2024, citing manufacturing constraints, reduced patient access, and availability of alternatives like Tresiba (insulin degludec).<\/p>\n\n\n\n<p>Levemir, first approved in the US in 2005, is a long-acting insulin analogue used for once- or twice-daily injection to provide a baseline insulin function for up to 24 hours. The decision by Novo Nordisk came shortly after the company reduced insulin prices by up to 75% and introduced a cap on insulin costs at no more than USD 35 per month. At the time, Novo Nordisk stated that it was confident patients would have access to alternative treatments in the US.<\/p>\n\n\n\n<p>The senators wrote to Novo Nordisk in April 2024 to protest the decision, expressing alarm that the move failed to consider patient access to affordable substitutes. Reuters reported that a meeting between Shaheen&#8217;s office and Novo Nordisk was scheduled for this week, though details were not provided, and Novo Nordisk has not confirmed the meeting.<\/p>\n\n\n\n<p>Novo Nordisk has indicated it is struggling to free up manufacturing capacity for its new generation of GLP-1-targeted anti-obesity and type 2 diabetes treatments, Wegovy\/Ozempic (semaglutide). The company&#8217;s investment plans for 2024 include a significant increase in production investment to meet the growing global demand for its medicines, with a particular focus on expanding capacity for current and future injectable treatments for obesity and other serious chronic diseases.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,4],"tags":[1250,148,860],"class_list":["post-1658","post","type-post","status-publish","format-standard","hentry","category-company","category-policy-regulatory","tag-cph-novo-b","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Faces US Senators&#039; Scrutiny Over Levemir Withdrawal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo Nordisk&#039;s (NYSE: NVO; CPH: NOVO-B) decision to discontinue the sales of its long-acting insulin brand Levemir (insulin detemir) in the US market. The company announced in November 2023 its intention to cease distribution by the end of 2024, citing manufacturing constraints, reduced patient access, and availability of alternatives like Tresiba (insulin degludec).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1658\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Faces US Senators&#039; Scrutiny Over Levemir Withdrawal\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1658\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-16T13:29:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-15T06:21:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1658#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1658\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Faces US Senators&#8217; Scrutiny Over Levemir Withdrawal\",\"datePublished\":\"2024-07-16T13:29:38+00:00\",\"dateModified\":\"2024-10-15T06:21:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1658\"},\"wordCount\":280,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CPH: NOVO-B\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1658#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1658\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1658\",\"name\":\"Novo Nordisk Faces US Senators' Scrutiny Over Levemir Withdrawal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-07-16T13:29:38+00:00\",\"dateModified\":\"2024-10-15T06:21:25+00:00\",\"description\":\"US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo Nordisk's (NYSE: NVO; CPH: NOVO-B) decision to discontinue the sales of its long-acting insulin brand Levemir (insulin detemir) in the US market. The company announced in November 2023 its intention to cease distribution by the end of 2024, citing manufacturing constraints, reduced patient access, and availability of alternatives like Tresiba (insulin degludec).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1658#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1658\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1658#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Faces US Senators&#8217; Scrutiny Over Levemir Withdrawal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Faces US Senators' Scrutiny Over Levemir Withdrawal - Insight, China&#039;s Pharmaceutical Industry","description":"US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo Nordisk's (NYSE: NVO; CPH: NOVO-B) decision to discontinue the sales of its long-acting insulin brand Levemir (insulin detemir) in the US market. The company announced in November 2023 its intention to cease distribution by the end of 2024, citing manufacturing constraints, reduced patient access, and availability of alternatives like Tresiba (insulin degludec).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1658","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Faces US Senators' Scrutiny Over Levemir Withdrawal","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1658","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-07-16T13:29:38+00:00","article_modified_time":"2024-10-15T06:21:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1658#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1658"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Faces US Senators&#8217; Scrutiny Over Levemir Withdrawal","datePublished":"2024-07-16T13:29:38+00:00","dateModified":"2024-10-15T06:21:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1658"},"wordCount":280,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CPH: NOVO-B","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1658#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1658","url":"https:\/\/flcube.com\/?p=1658","name":"Novo Nordisk Faces US Senators' Scrutiny Over Levemir Withdrawal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-07-16T13:29:38+00:00","dateModified":"2024-10-15T06:21:25+00:00","description":"US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo Nordisk's (NYSE: NVO; CPH: NOVO-B) decision to discontinue the sales of its long-acting insulin brand Levemir (insulin detemir) in the US market. The company announced in November 2023 its intention to cease distribution by the end of 2024, citing manufacturing constraints, reduced patient access, and availability of alternatives like Tresiba (insulin degludec).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1658#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1658"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1658#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Faces US Senators&#8217; Scrutiny Over Levemir Withdrawal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1658"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1658\/revisions"}],"predecessor-version":[{"id":6739,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1658\/revisions\/6739"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}